Be the first to like this
IntroductionOsteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Across the seven major markets, sales for osteoporosis drugs grew with a compound annual growth rate (CAGR) of 2.0% from 2005 to $6.9 billion in 2009. Nonetheless, several promising pipeline drugs will help the market resume growth.ScopePatient potential analysis across the seven major markets and BRIC nations (Brazil, Russia, India, and China).Review of the key clinical and environmental unmet needs supported by insight from key opinion leaders across the US, Europe and Japan.Analysis of target product profile for an osteoporosis drug. R&D pipeline analysis with detailed profiles and forecasts of key agents, including Amgen's Prolia (denosumab) and Merck's odanacatib.HighlightsOsteoporosis prevalence is expected to increase due to the general aging population. By 2020, the total male and female osteoporosis population is forecast to increase by 16.0% from 168 million in 2010 to reach 188 million patients across the seven major markets.Despite some long-term safety and cost concerns, Prolia will become the osteoporosis market leader by 2019, but will not achieve blockbuster sales. Moreover, its position will be threatened should odanacatib show a superior clinical profile.Over the forecast period, three new anabolic drugs are due to launch. These will have to compete on cost, efficacy and safety with the class leader Forteo (teriparatide, Eli Lilly). While these drugs will address some unmet needs, early clinical data suggests that more potent drugs such Amgen's antisclerostin may dominate the market in the future.Reasons to PurchaseUnderstand patient population dynamics Gain insight into shortcomings of current osteoporosis treatment and to what extent pipeline drugs will address these unmet clinical needs.Identify licensing opportunities based on company portfolio and market needs.